Clinical Trials Logo
  1. Home
  2. Metastatic Liver Cancer
  3. NCT02787954

Prospective Tumor Response Evaluation — Liver  

Hepatocellular Cancer Clinical Trial

Official title:
Prospective Evaluation of Tumor Response to Cancer Treatment Therapies

Clinical Trial Summary

The purpose of this study is to determine if MRI imaging can detect genetic, proteomic, and metabolomic characteristics of liver tumors. The study also aims to determine if these imaging characteristics are correlated with clinical outcomes.

Clinical Trial Description

For each treatment arm, pre-procedural MRI and post procedural MRI will be obtained. Pre-procedural biopsies will be obtained, if possible. Pretreatment genetic expression, proteomic, or metabolomic patterns from the tumor samples will be assessed. Imaging characteristics from tumors will be extracted using automated software—the study will apply a computational analysis system with the capability to extract and analyze imaging characteristics and correlate them to genetic expression, proteomic, and metabolomic tumor characteristics. Imaging findings will be correlated to clinical outcomes and genetic, proteomic, and metabolomic findings to determine association. Imaging findings and genomic, proteomic, and metabolomic tumor characteristics will be correlated to clinical outcomes (time to recurrence, overall survival, 3-month, 6-month, and 1-year survival). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02787954
Study type Observational [Patient Registry]
Source The University of Texas Health Science Center, Houston
Contact
Status Terminated
Phase
Start date January 2016
Completion date April 2017
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03971201 - A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion Phase 2
Recruiting NCT05489250 - The PLATON Network
Recruiting NCT04484636 - PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study) N/A
Completed NCT01967823 - T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer Phase 2
Terminated NCT00878215 - Clinical Application of Image-Guided Liver Surgery Phase 2
Completed NCT04212286 - Comparing the Diagnostic Efficiencies of CEUS and EOB-MRI in Patients With High Risk of HCC N/A
Recruiting NCT05992220 - Atezolizumab Plus Bevacizumab Alone or Combined With External Beam Radiotherapy for HCC With Macrovascular Invasion Phase 2
Completed NCT02073435 - A2ALL-Patients Safety System Improvements in Living Donor Liver Transplantation
Active, not recruiting NCT01522937 - A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer Phase 2
Terminated NCT05061537 - Study of PF-07263689 in Participants With Selected Advanced Solid Tumors Phase 1
Active, not recruiting NCT04166240 - Measuring and Improving the Safety of Test Result Follow-Up N/A
Withdrawn NCT02288507 - Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer Phase 1
Terminated NCT03026803 - A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer Phase 2
Active, not recruiting NCT04682847 - Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers
Active, not recruiting NCT05100082 - Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular Carcinoma
Active, not recruiting NCT03195699 - Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers Phase 1
Completed NCT02616692 - HCC Patient Preferences in Japan N/A
Active, not recruiting NCT03132792 - AFPᶜ³³²T in Advanced HCC Phase 1
Recruiting NCT01849588 - Sorafenib for Hepatocellular Cancer With Chronic Hepatitis C Phase 4
Completed NCT00997022 - Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients Phase 1